Pillars of growth
Enoxaparin BIOSIMILAR
Enoxaparin Biosimilar represents an excellent growth opportunity for ROVI considering the significant medical need. Enoxaparin Biosimilar was launched in the UK in March 2018 and is marketed under the brand AROVI®.
Enoxaparin BIOSIMILAR
Enoxaparin Biosimilar represents an excellent growth opportunity for ROVI considering the significant medical need. Enoxaparin Biosimilar was launched in the UK in March 2018 and is marketed under the brand AROVI®.
Research, Development and Innovation
(R&D and I)
R&D and I as an engine for future growth.
Find out +
Contract Manufacturing
High production capacity with four manufacturing plants for pre-filled syringes, oral solids and active principles.
Rovi in figures
304
millions euros2018 Operating Revenue
56
countries
Bemiparin international presencewith 22 international partners
6
plants
for the production of own products and third party products in Spain
32,4 Mn€
Invested in R&D in 2018committed to innovation
7 countries
Direct presencethrough subsidiaries to market Enoxaparin
Information for investors
Detailed information for investors and shareholders. All of ROVI’s information, results and figures presented clearly and transparently.
Commitment to transparency
Our society expects the pharmaceutical industry to be able to make the best possible medicines available to them. To achieve this objective, it is necessary to invest in Research and Development, as well as in training, requiring close collaboration with Healthcare Professionals (HCPs), Healthcare Organizations (HCOs) and Patient Organizations (POs). This valuable exchange of knowledge and experience makes it possible to have the most innovative treatments, which improves the life expectancy and quality of life of patients.
It is necessary for these collaborations to be transparent and for society to be able to trust that they are due to the need to develop new medicines, to constant updating of HCPs according to scientific evidence and its application to clinical practice, all of this with the common goal of providing better patient care.
When collaborating with medical experts, we comply with applicable laws and regulations such as the EFPIA Disclosure Code in Europe and fully respect the independence and integrity of these professionals.